OTC$SMNR
Semnur Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Denali Capital reported Q2 2025, net loss of $405.8M, diluted EPS of $-8.12.
For Q2 2025, Denali Capital reported a net loss of $405.8M, diluted EPS was $-8.12. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $405.8M.
- Diluted EPS $-8.12.
- Denali Capital MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Denali Capital Acquisition-A · Revenue · Quarterly
$50M
Forward guidance
Clinical-stage and growth biotech discuss trial milestones, launch readiness, and cash runway.
Tailwinds
- Pipeline and regulatory milestones.
- Cash runway from recent financings.
- Partnership or licensing potential.
Headwinds
- Trial or approval delays.
- Commercial launch execution risk.
- Dilution from equity raises.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
+0.2%
Avg return
Earnings day
—
Avg return
5 days after
—
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.5%
Q4 2023
Best reaction
-8.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | — | — | — | |
| Q3 2024 | -0.8% | — | — | |
| Q2 2024 | +1.6% | — | — | |
| Q1 2024 | -8.0% | — | — | |
| Q4 2023 | +8.5% | — | — | |
| Q3 2023 | +0.1% | — | — | |
| Q2 2023 | +0.2% | — | — | |
| Q1 2023 | +0.0% | — | — | |
| Q4 2022 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro